{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:40:24Z","timestamp":1793580024688,"version":"4.5.0"},"reference-count":150,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01183-z","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:28:11Z","timestamp":1763198891000},"page":"937-953","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting DNA Damage Repair Pathways Beyond PARP Inhibition"],"prefix":"10.1007","volume":"20","author":[{"given":"Eve","family":"Merry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-7221","authenticated-orcid":false,"given":"Charlie","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"issue":"7267","key":"1183_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071\u20138.","journal-title":"Nature"},{"issue":"5868","key":"1183_CR2","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","volume":"319","author":"TD Halazonetis","year":"2008","unstructured":"Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319(5868):1352\u20135.","journal-title":"Science"},{"issue":"5","key":"1183_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"7035","key":"1183_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913\u20137.","journal-title":"Nature"},{"issue":"7035","key":"1183_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"1","key":"1183_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/genetics\/59.1.37","volume":"59","author":"JC Lucchesi","year":"1968","unstructured":"Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics. 1968;59(1):37\u201344.","journal-title":"Genetics"},{"issue":"21","key":"1183_CR7","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang S, Yin N, Das BB, Renaud A, Zhang Y, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"issue":"1","key":"1183_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","volume":"9","author":"SJ Pettitt","year":"2018","unstructured":"Pettitt SJ, Krastev DB, Brandsma I, Dr\u00e9an A, Song F, Aleksandrov R, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun. 2018;9(1):1849.","journal-title":"Nat Commun"},{"issue":"25","key":"1183_CR9","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1200\/JCO.18.02050","volume":"37","author":"C Gourley","year":"2019","unstructured":"Gourley C, Balma\u00f1a J, Ledermann JA, Serra V, Dent R, Loibl S, et al. Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019;37(25):2257\u201369.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1183_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526\u201335.","journal-title":"Ann Oncol"},{"issue":"4","key":"1183_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558\u201366.","journal-title":"Ann Oncol"},{"issue":"25","key":"1183_CR12","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405.","journal-title":"N Engl J Med"},{"issue":"22","key":"1183_CR13","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"4","key":"1183_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"1183_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41571-024-00966-z","volume":"22","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi NYL, Gallo D, Torrado C, Nardo M, Durocher D, Yap TA. Synthetic lethal strategies for the development of cancer therapeutics. Nat Rev Clin Oncol. 2025;22(1):46\u201364.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1183_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4161\/cc.11.5.19482","volume":"11","author":"C Fathers","year":"2012","unstructured":"Fathers C, Drayton RM, Solovieva S, Bryant HE. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. Cell Cycle. 2012;11(5):990\u20137.","journal-title":"Cell Cycle"},{"key":"1183_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.640755","volume":"9","author":"H Lu","year":"2021","unstructured":"Lu H, Davis AJ. Human RecQ helicases in DNA double-strand break repair. Front Cell Dev Biol. 2021;9:640755.","journal-title":"Front Cell Dev Biol"},{"key":"1183_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1476-4598-12-91","volume":"12","author":"I Garc\u00eda-Santisteban","year":"2013","unstructured":"Garc\u00eda-Santisteban I, Peters GJ, Giovannetti E, Rodr\u00edguez JA. USP1 deubiquitinase: cellular functions, regulatory mechanisms and emerging potential as target in cancer therapy. Mol Cancer. 2013;12:91.","journal-title":"Mol Cancer"},{"issue":"4","key":"1183_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pili\u00e9 PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21(4):278\u201393.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1183_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","volume":"7","author":"NYL Ngoi","year":"2021","unstructured":"Ngoi NYL, Pham MM, Tan DSP, Yap TA. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer. 2021;7(10):930\u201357.","journal-title":"Trends Cancer."},{"issue":"27","key":"1183_CR21","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, De Miguel Luken MJ, et al. Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol. 2020;38(27):3195\u2013204.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1183_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J Clin Invest. 2024;134(2):e175369.","journal-title":"J Clin Invest"},{"issue":"23","key":"1183_CR23","doi-asserted-by":"publisher","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","volume":"70","author":"O Gilad","year":"2010","unstructured":"Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010;70(23):9693\u2013702.","journal-title":"Cancer Res"},{"issue":"5","key":"1183_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127(5):582\u201395.","journal-title":"Blood"},{"issue":"9","key":"1183_CR25","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","volume":"123","author":"CR Dunlop","year":"2020","unstructured":"Dunlop CR, Wallez Y, Johnson TI, Bernaldo de Quir\u00f3s Fern\u00e1ndez S, Durant ST, Cadogan EB, et al. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br J Cancer. 2020;123(9):1424\u201336.","journal-title":"Br J Cancer"},{"issue":"3","key":"1183_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med. 2024;30(3):716\u201329.","journal-title":"Nat Med"},{"issue":"1","key":"1183_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 2021;11(1):80\u201391.","journal-title":"Cancer Discov"},{"issue":"2","key":"1183_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111081","volume":"40","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann M, Bernier C, Kaiser B, Fournier S, Li L, Desjardins J, et al. Guiding ATR and PARP inhibitor combinations with chemogenomic screens. Cell Rep. 2022;40(2):111081.","journal-title":"Cell Rep"},{"key":"1183_CR29","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun. 2016;7:13837.","journal-title":"Nat Commun"},{"issue":"2","key":"1183_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaa005","volume":"2","author":"K Kurashima","year":"2020","unstructured":"Kurashima K, Kashiwagi H, Shimomura I, Suzuki A, Takeshita F, Mazevet M, et al. SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. NAR Cancer. 2020;2(2):zcaa005.","journal-title":"NAR Cancer"},{"issue":"14","key":"1183_CR31","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41388-018-0606-4","volume":"38","author":"C Wang","year":"2019","unstructured":"Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, et al. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene. 2019;38(14):2451\u201363.","journal-title":"Oncogene"},{"issue":"6","key":"1183_CR32","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Fontana E, Lee EK, Spigel DR, H\u00f8jgaard M, Lheureux S, et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023;29(6):1400\u201311.","journal-title":"Nat Med"},{"issue":"7","key":"1183_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(7):957\u201368.","journal-title":"Lancet Oncol"},{"key":"1183_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00635","volume":"8","author":"PA Konstantinopoulos","year":"2024","unstructured":"Konstantinopoulos PA, Cheng SC, Lee EK, da Costa AABA, Gulhan D, Wahner Hendrickson AE, et al. Randomized phase II study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: final overall survival and biomarker analyses. JCO Precis Oncol. 2024;8:e2300635.","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"1183_CR35","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","volume":"9","author":"N Takahashi","year":"2023","unstructured":"Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, et al. Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2023;9(12):1669\u201377.","journal-title":"JAMA Oncol"},{"issue":"15_Suppl","key":"1183_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3503","volume":"38","author":"J Lee","year":"2020","unstructured":"Lee J, Tae Kim S, Smith S, Mortimer PG, Loemb\u00e9 B, Hong J, et al. Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199). J Clin Oncol. 2020;38(15_Suppl):3503.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1183_CR37","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap TA, Krebs MG, Postel-Vinay S, El-Khouiery A, Soria JC, Lopez J, et al. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2021;27(19):5213\u201324.","journal-title":"Clin Cancer Res"},{"issue":"16_Suppl.","key":"1183_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3111","volume":"40","author":"N Ngoi","year":"2022","unstructured":"Ngoi N, Lin HY, Dumbrava EE, Fu S, Karp DD, Naing A, et al. Baseline predictors of hematological toxicity in patients with advanced cancer treated with ATR inhibitors in phase I\/II clinical trials. J Clin Oncol. 2022;40(16_Suppl.):3111.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1183_CR39","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djae098","volume":"116","author":"E Fontana","year":"2024","unstructured":"Fontana E, Rosen E, Lee EK, H\u00f8jgaard M, Mettu NB, Lheureux S, et al. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst. 2024;116(9):1439\u201349.","journal-title":"J Natl Cancer Inst"},{"issue":"8_Suppl._1","key":"1183_CR40","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2905","volume":"85","author":"HM Robinson","year":"2025","unstructured":"Robinson HM, Piscitello D, Elinati E, Armstrong L, Graham E, Peripolli S, et al. Abstract 2905: combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors. Cancer Res. 2025;85(8_Suppl._1):2905.","journal-title":"Cancer Res"},{"issue":"6_Suppl","key":"1183_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.088","volume":"40","author":"ZR Reichert","year":"2022","unstructured":"Reichert ZR, Devitt ME, Alumkal JJ, Smith DC, Caram MV, Palmbos P, et al. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). J Clin Oncol. 2022;40(6_Suppl):88.","journal-title":"J Clin Oncol"},{"key":"1183_CR42","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.annonc.2022.03.180","volume":"33","author":"A Tutt","year":"2022","unstructured":"Tutt A, Nowecki Z, Szoszkiewicz R, Im SA, Arkenau HT, Armstrong A, et al. 161O VIOLETTE: randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2022;33:S194\u20135.","journal-title":"Ann Oncol"},{"issue":"16_Suppl.","key":"1183_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5510","volume":"42","author":"F Simpkins","year":"2024","unstructured":"Simpkins F, Nasioudis D, Wethington SL, Martin LP, Tanyi JL, Latif NA, et al. Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). J Clin Oncol. 2024;42(16_Suppl.):5510.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1183_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100814","volume":"8","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Leary A, Stewart JR, Dewan M, Lheureux S, Clamp AR, et al. 34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: results from the ENGOT\/GYN1\/NCRI ATARI trial. ESMO Open. 2023;8(1):100814.","journal-title":"ESMO Open"},{"issue":"8_Suppl","key":"1183_CR45","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT018","volume":"83","author":"TA Yap","year":"2023","unstructured":"Yap TA, Yadav S, Herzberg B, Carneiro BA, Fontana E, H\u00f8jgaard M, et al. Abstract CT018: safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations. Cancer Res. 2023;83(8_Suppl):CT018.","journal-title":"Cancer Res"},{"issue":"1","key":"1183_CR46","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11(1):3726.","journal-title":"Nat Commun"},{"issue":"3","key":"1183_CR47","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1101\/gad.290957.116","volume":"31","author":"SA Yazinski","year":"2017","unstructured":"Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017;31(3):318\u201332.","journal-title":"Genes Dev"},{"issue":"1","key":"1183_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","volume":"19","author":"LC Riches","year":"2020","unstructured":"Riches LC, Trinidad AG, Hughes G, Jones GN, Hughes AM, Thomason AG, et al. Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses preclinically. Mol Cancer Ther. 2020;19(1):13\u201325.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1183_CR49","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1186\/s12885-022-10084-7","volume":"22","author":"SL Davis","year":"2022","unstructured":"Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, et al. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. BMC Cancer. 2022;22(1):1107.","journal-title":"BMC Cancer"},{"issue":"2","key":"1183_CR50","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.ijrobp.2024.07.217","volume":"120","author":"JT Yang","year":"2024","unstructured":"Yang JT, Wen PY, Imber BS, Drappatz J, Jena R, Forst D, et al. Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma. Int J Radiat Oncol Biol Phys. 2024;120(2):S119\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"1183_CR51","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/j.jtho.2023.09.509","volume":"18","author":"A Horne","year":"2023","unstructured":"Horne A, Brown S, Coyle V, Franks K, Hassani A, Harrow S, et al. P2.01\u201304 An update on the CONCORDE study: a phase Ib platform study of novel agents in combination with conventional radiotherapy in NSCLC. J Thorac Oncol. 2023;18(11):S296\u20137.","journal-title":"J Thorac Oncol"},{"issue":"1_Suppl","key":"1183_CR52","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-17-A094","volume":"17","author":"W Abida","year":"2018","unstructured":"Abida W, Bang YJ, Carter L, Azaro A, Krebs M, Im SA, et al. Abstract A094: phase i modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM study, module 1). Mol Cancer Ther. 2018;17(1_Suppl):A094.","journal-title":"Mol Cancer Ther"},{"issue":"7_Suppl","key":"1183_CR53","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT063","volume":"84","author":"LL Siu","year":"2024","unstructured":"Siu LL, Cabanas EG, Boni V, Tolcher AW, Garcia ES, Fuentes-Antr\u00e1s J, et al. Abstract CT063: phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors. Cancer Res. 2024;84(7_Suppl):CT063.","journal-title":"Cancer Res"},{"issue":"1","key":"1183_CR54","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","volume":"10","author":"JHL Fok","year":"2019","unstructured":"Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, Wijnhoven PWG, Follia V, James N, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019;10(1):5065.","journal-title":"Nat Commun"},{"issue":"14","key":"1183_CR55","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1158\/1078-0432.CCR-17-3421","volume":"24","author":"JC Bendell","year":"2018","unstructured":"Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, et al. A first-in-human phase 1 study of LY3023414, an oral PI3K\/mTOR dual inhibitor, in patients with advanced cancer. Clin Cancer Res. 2018;24(14):3253\u201362.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1183_CR56","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1007\/s10637-020-00968-5","volume":"38","author":"S Kondo","year":"2020","unstructured":"Kondo S, Tajimi M, Funai T, Inoue K, Asou H, Ranka VK, et al. Phase 1 dose-escalation study of a novel oral PI3K\/mTOR dual inhibitor, LY3023414, in patients with cancer. Invest New Drugs. 2020;38(6):1836\u201345.","journal-title":"Invest New Drugs"},{"issue":"6","key":"1183_CR57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/cncr.32677","volume":"126","author":"MM Rubinstein","year":"2020","unstructured":"Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer. 2020;126(6):1274\u201382.","journal-title":"Cancer"},{"key":"1183_CR58","doi-asserted-by":"publisher","first-page":"10463","DOI":"10.2147\/CMAR.S208720","volume":"11","author":"P Munster","year":"2019","unstructured":"Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, et al. First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy. Cancer Manag Res. 2019;11:10463\u201376.","journal-title":"Cancer Manag Res."},{"issue":"10","key":"1183_CR59","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1349-7006.2003.tb01372.x","volume":"94","author":"S Shintani","year":"2003","unstructured":"Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro KI, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 2003;94(10):894\u2013900.","journal-title":"Cancer Sci"},{"issue":"5","key":"1183_CR60","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.bjc.6605201","volume":"101","author":"C Beskow","year":"2009","unstructured":"Beskow C, Skikuniene J, Holgersson A, Nilsson B, Lewensohn R, Kanter L, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer. 2009;101(5):816\u201321.","journal-title":"Br J Cancer"},{"issue":"3","key":"1183_CR61","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1158\/1078-0432.CCR-23-1531","volume":"30","author":"A Laroche-Clary","year":"2024","unstructured":"Laroche-Clary A, Josensi C, Derieppe MA, Belhomme S, Vendrely V, Perret R, et al. Selective DNA-PK inhibition enhances chemotherapy and ionizing radiation activity in soft-tissue sarcomas. Clin Cancer Res. 2024;30(3):629\u201337.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1183_CR62","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1158\/1535-7163.MCT-21-0420","volume":"21","author":"A Anastasia","year":"2022","unstructured":"Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, et al. The DNA-PK inhibitor AZD7648 sensitizes patient-derived ovarian cancer xenografts to pegylated liposomal doxorubicin and olaparib preventing abdominal metastases. Mol Cancer Ther. 2022;21(4):555\u201367.","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"1183_CR63","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1158\/1078-0432.CCR-20-3701","volume":"27","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Karmokar A, Farrington PM, James NH, Ramos-Montoya A, Bickerton SJ, et al. Inhibition of DNA-PK with AZD7648 sensitizes tumor cells to radiotherapy and induces type I IFN-dependent durable tumor control. Clin Cancer Res. 2021;27(15):4353\u201366.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1183_CR64","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/1535-7163.MCT-19-0734","volume":"19","author":"FT Zenke","year":"2020","unstructured":"Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, et al. Pharmacologic inhibitor of DNA-PK, M3814, potentiates radiotherapy and regresses human tumors in mouse models. Mol Cancer Ther. 2020;19(5):1091\u2013101.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1183_CR65","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/2159-8290.CD-13-0907","volume":"4","author":"F Dietlein","year":"2014","unstructured":"Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014;4(5):592\u2013605.","journal-title":"Cancer Discov"},{"issue":"3","key":"1183_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.molcel.2009.04.025","volume":"34","author":"E Call\u00e9n","year":"2009","unstructured":"Call\u00e9n E, Jankovic M, Wong N, Zha S, Chen HT, Difilippantonio S, et al. Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes. Mol Cell. 2009;34(3):285\u201397.","journal-title":"Mol Cell"},{"issue":"2","key":"1183_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41416-025-03053-x","volume":"133","author":"TA Yap","year":"2025","unstructured":"Yap TA, LoRusso P, Miller RE, Kristeleit R, Paulovich AG, McMorn S, et al. The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human phase I\/IIa study. Br J Cancer. 2025;133(2):168\u201377.","journal-title":"Br J Cancer"},{"issue":"3","key":"1183_CR68","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ijrobp.2023.09.024","volume":"118","author":"M Samuels","year":"2024","unstructured":"Samuels M, Falkenius J, Bar-Ad V, Dunst J, Van Triest B, Yachnin J, et al. A phase 1 study of the DNA-PK inhibitor peposertib in combination with radiation therapy with or without cisplatin in patients with advanced head and neck tumors. Int J Radiat Oncol Biol Phys. 2024;118(3):743\u201356.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1183_CR69","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1158\/1078-0432.CCR-23-1129","volume":"30","author":"PB Romesser","year":"2024","unstructured":"Romesser PB, Capdevila J, Garcia-Carbonero R, Philip T, Fernandez Martos C, Tuli R, et al. A phase Ib study of the DNA-PK inhibitor peposertib combined with neoadjuvant chemoradiation in patients with locally advanced rectal cancer. Clin Cancer Res. 2024;30(4):695\u2013702.","journal-title":"Clin Cancer Res"},{"issue":"16_Suppl","key":"1183_CR70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2076","volume":"42","author":"N Majd","year":"2024","unstructured":"Majd N, Yeboa D, Wang S, Weathers SPS, Yuan Y, Al Anssari H, et al. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. J Clin Oncol. 2024;42(16_Suppl):2076.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1183_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41467-018-07729-2","volume":"10","author":"G Balmus","year":"2019","unstructured":"Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, et al. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. Nat Commun. 2019;10(1):87.","journal-title":"Nat Commun"},{"issue":"21","key":"1183_CR72","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1007\/s00018-013-1307-3","volume":"70","author":"M Patil","year":"2013","unstructured":"Patil M, Pabla N, Dong Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci. 2013;70(21):4009\u201321.","journal-title":"Cell Mol Life Sci"},{"issue":"15","key":"1183_CR73","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","volume":"34","author":"D Hong","year":"2016","unstructured":"Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, et al. Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. J Clin Oncol. 2016;34(15):1764\u201371.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1183_CR74","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1111\/cas.13750","volume":"109","author":"S Iwasa","year":"2018","unstructured":"Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, et al. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. Cancer Sci. 2018;109(10):3216\u201323.","journal-title":"Cancer Sci"},{"issue":"2","key":"1183_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","volume":"167","author":"PA Konstantinopoulos","year":"2022","unstructured":"Konstantinopoulos PA, Lee JM, Gao B, Miller R, Lee JY, Colombo N, et al. A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecol Oncol. 2022;167(2):213\u201325.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1183_CR76","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11523-021-00835-0","volume":"16","author":"KN Moore","year":"2021","unstructured":"Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, et al. A phase 1b trial of prexasertib in combination with standard-of-care agents in advanced or metastatic cancer. Target Oncol. 2021;16(5):569\u201389.","journal-title":"Target Oncol"},{"issue":"2","key":"1183_CR77","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","volume":"29","author":"R Jones","year":"2023","unstructured":"Jones R, Plummer R, Moreno V, Carter L, Roda D, Garralda E, et al. A phase I\/II trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clin Cancer Res. 2023;29(2):331\u201340.","journal-title":"Clin Cancer Res"},{"key":"1183_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216057","volume":"555","author":"RL Hollis","year":"2023","unstructured":"Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023;555:216057.","journal-title":"Cancer Lett"},{"issue":"10","key":"1183_CR79","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s00262-021-02910-x","volume":"70","author":"KT Do","year":"2021","unstructured":"Do KT, Manuszak C, Thrash E, Giobbie-Hurder A, Hu J, Kelland S, et al. Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors. Cancer Immunol Immunother. 2021;70(10):2991\u20133000.","journal-title":"Cancer Immunol Immunother"},{"issue":"67","key":"1183_CR80","doi-asserted-by":"publisher","first-page":"111026","DOI":"10.18632\/oncotarget.22195","volume":"8","author":"E Brill","year":"2017","unstructured":"Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget. 2017;8(67):111026\u201340.","journal-title":"Oncotarget"},{"issue":"14","key":"1183_CR81","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/0008-5472.CAN-16-3409","volume":"77","author":"T Sen","year":"2017","unstructured":"Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, et al. Chk1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. Cancer Res. 2017;77(14):3870\u201384.","journal-title":"Cancer Res"},{"issue":"20","key":"1183_CR82","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-19-0448","volume":"25","author":"K Parmar","year":"2019","unstructured":"Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, et al. The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition. Clin Cancer Res. 2019;25(20):6127\u201340.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1183_CR83","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1158\/1078-0432.CCR-21-1279","volume":"27","author":"KT Do","year":"2021","unstructured":"Do KT, Kochupurakkal B, Kelland S, de Jonge A, Hedglin J, Powers A, et al. Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors. Clin Cancer Res. 2021;27(17):4710\u20136.","journal-title":"Clin Cancer Res"},{"key":"1183_CR84","unstructured":"Debiopharm. Cancer target back in contention with more selective inhibitor. nature research custom media. https:\/\/www.nature.com\/articles\/d42473-024-00266-1. Accessed 29 Oct 2025."},{"issue":"18","key":"1183_CR85","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","volume":"26","author":"AM Oza","year":"2020","unstructured":"Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marm\u00e9 F, Provencher D, et al. A biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res. 2020;26(18):4767\u201376.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"1183_CR86","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.21.01435","volume":"39","author":"JF Seligmann","year":"2021","unstructured":"Seligmann JF, Fisher DJ, Brown LC, Adams RA, Graham J, Quirke P, et al. Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. J Clin Oncol. 2021;39(33):3705\u201315.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1183_CR87","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO-24-01606","volume":"43","author":"JF Liu","year":"2025","unstructured":"Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, et al. ADAGIO: a phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma. J Clin Oncol. 2025;43(26):2897\u2013907.","journal-title":"J Clin Oncol"},{"issue":"16_Suppl.","key":"1183_CR88","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3012","volume":"41","author":"H Gelderblom","year":"2023","unstructured":"Gelderblom H, Jalving M, Desar I, Saavedra O, Gietema JA, Van Ravensteijn S, et al. Debio 0123\u2013101: a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors \u2014 safety, pharmacokinetic, and preliminary antitumor activity data. J Clin Oncol. 2023;41(16_Suppl.):3012.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1183_CR89","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10637-023-01371-6","volume":"41","author":"GS Falchook","year":"2023","unstructured":"Falchook GS, Sachdev J, Imedio ER, Kumar S, Mugundu GM, Jenkins S, et al. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors. Invest New Drugs. 2023;41(3):493\u2013502.","journal-title":"Invest New Drugs"},{"key":"1183_CR90","volume":"39","author":"S Kondo","year":"2024","unstructured":"Kondo S, Katsuya Y, Yonemori K, Komuro K, Sugeno M, Kawata T, et al. Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: a phase I, open-label study. Cancer Treat Res Commun. 2024;39:100809.","journal-title":"Cancer Treat Res Commun"},{"issue":"16_Suppl.","key":"1183_CR91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3120","volume":"42","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos KP, Sharma M, Dummer R, Colombo I, Ramelyte E, Seamon L, et al. Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: safety, pharmacokinetic, and preliminary antitumor activity data. J Clin Oncol. 2024;42(16_Suppl.):3120.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1183_CR92","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, et al. Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. Clin Cancer Res. 2018;24(24):6594\u2013610.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1183_CR93","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, et al. Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. J Clin Oncol. 2023;41(9):1725\u201334.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1183_CR94","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","volume":"2","author":"M Aarts","year":"2012","unstructured":"Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012;2(6):524\u201339.","journal-title":"Cancer Discov"},{"issue":"9","key":"1183_CR95","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","volume":"17","author":"NV Rajeshkumar","year":"2011","unstructured":"Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011;17(9):2799\u2013806.","journal-title":"Clin Cancer Res"},{"issue":"36","key":"1183_CR96","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RMJM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354\u201361.","journal-title":"J Clin Oncol"},{"key":"1183_CR97","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","volume":"174","author":"A Embaby","year":"2023","unstructured":"Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: a biomarker-enriched phase II study. Gynecol Oncol. 2023;174:239\u201346.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1183_CR98","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ccell.2015.09.015","volume":"28","author":"SX Pfister","year":"2015","unstructured":"Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, et al. Inhibiting WEE1 selectively kills histone H3K36me3-deficient cancers by dNTP starvation. Cancer Cell. 2015;28(5):557\u201368.","journal-title":"Cancer Cell"},{"issue":"7","key":"1183_CR99","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1158\/2767-9764.CRC-24-0213","volume":"4","author":"E Maldonado","year":"2024","unstructured":"Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, et al. A phase II trial of the WEE1 inhibitor adavosertib in SETD2-altered advanced solid tumor malignancies (NCI 10170). Cancer Res Commun. 2024;4(7):1793\u2013801.","journal-title":"Cancer Res Commun"},{"issue":"10271","key":"1183_CR100","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10271):281\u201392.","journal-title":"Lancet"},{"issue":"36","key":"1183_CR101","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RMJM, Pavlick AC, Tibes R, Rosen L, Razak ARA, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34(36):4371\u201380.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1183_CR102","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-17-2805","volume":"24","author":"A Lallo","year":"2018","unstructured":"Lallo A, Frese KK, Morrow CJ, Sloane R, Gulati S, Schenk MW, et al. The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clin Cancer Res. 2018;24(20):5153\u201364.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"1183_CR103","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clin Cancer Res. 2022;28(20):4536\u201350.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1183_CR104","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","volume":"19","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Falchook GS, Wang JS, Fu S, Oza AM, Imedio ER, et al. Adavosertib in combination with olaparib in patients with refractory solid tumors: an open-label, dose-finding, and dose-expansion phase Ib trial. Target Oncol. 2024;19(6):879\u201392.","journal-title":"Target Oncol"},{"issue":"15_Suppl.","key":"1183_CR105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","volume":"39","author":"SN Westin","year":"2021","unstructured":"Westin SN, Coleman RL, Fellman BM, Yuan Y, Sood AK, Soliman PT, et al. EFFORT: efficacy of adavosertib in parp resistance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J Clin Oncol. 2021;39(15_Suppl.):5505.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1183_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061503","volume":"12","author":"MK Gomez","year":"2020","unstructured":"Gomez MK, Illuzzi G, Colomer C, Churchman M, Hollis RL, O\u2019Connor MJ, et al. Identifying and overcoming mechanisms of PARP inhibitor resistance in homologous recombination repair-deficient and repair-proficient high grade serous ovarian cancer cells. Cancers (Basel). 2020;12(6):1503.","journal-title":"Cancers (Basel)"},{"key":"1183_CR107","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0959-8049(22)00822-X","volume":"174","author":"TA Yap","year":"2022","unstructured":"Yap TA, Ngoi N, Dumbrava EE, Karp DD, Rodon Ahnert J, Fu S, et al. NCI10329: phase Ib sequential trial of agents against DNA repair (STAR) study to investigate the sequential combination of the poly (ADP-ribose) polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA damage response (DDR)-aberrant advanced tumors, enriched for BRCA1\/2 mutated and CCNE1 amplified cancers. Eur J Cancer. 2022;174:S7.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1183_CR108","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1084\/jem.20121258","volume":"210","author":"KR Lamont","year":"2013","unstructured":"Lamont KR, Hasham MG, Donghia NM, Branca J, Chavaree M, Chase B, et al. Attenuating homologous recombination stimulates an AID-induced antileukemic effect. J Exp Med. 2013;210(5):1021\u201333.","journal-title":"J Exp Med"},{"key":"1183_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1221528","volume":"14","author":"J Jiao","year":"2023","unstructured":"Jiao J, Lv Z, Wang Y, Fan L, Yang A. The off-target effects of AID in carcinogenesis. Front Immunol. 2023;14:1221528.","journal-title":"Front Immunol"},{"key":"1183_CR110","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S0959-8049(22)00868-1","volume":"174","author":"B Bradley","year":"2022","unstructured":"Bradley B, Belmonte MA, Kansara S, Blank JL, Cryan L, Reilly NM, et al. Identification of the mechanism of action of CYT-0851, an inhibitor of monocarboxylate transporter (MCT) mediated lactate transport. Eur J Cancer. 2022;174:S24\u20135.","journal-title":"Eur J Cancer"},{"issue":"16_Suppl.","key":"1183_CR111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3084","volume":"40","author":"RC Lynch","year":"2022","unstructured":"Lynch RC, Munster PN, Advani RH, Hamadani M, Spigel DR, Falchook GS, et al. Phase 1 results of a phase 1\/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers. J Clin Oncol. 2022;40(16_Suppl.):3084.","journal-title":"J Clin Oncol"},{"issue":"12_Suppl","key":"1183_CR112","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-23-LB_A13","volume":"22","author":"E Swisher","year":"2023","unstructured":"Swisher E, Falchook GS, Munster PN, Beri N, Moore KN, Yap TA, et al. Abstract LB_A13: phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer. Mol Cancer Ther. 2023;22(12_Suppl):LB_A13.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1183_CR113","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.radonc.2011.08.013","volume":"101","author":"H Zhao","year":"2011","unstructured":"Zhao H, Luoto KR, Meng AX, Bristow RG. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011;101(1):59\u201365.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1183_CR114","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.11106","volume":"105","author":"LT Hansen","year":"2003","unstructured":"Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer. 2003;105(4):472\u20139.","journal-title":"Int J Cancer"},{"key":"1183_CR115","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1359-6349(10)71876-0","volume":"8","author":"M Azab","year":"2010","unstructured":"Azab M. Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts. Eur J Cancer Suppl. 2010;8:59.","journal-title":"Eur J Cancer Suppl"},{"issue":"1","key":"1183_CR116","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00280-014-2481-1","volume":"74","author":"M Mita","year":"2014","unstructured":"Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, et al. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(1):195\u2013204.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"46","key":"1183_CR117","doi-asserted-by":"publisher","first-page":"81441","DOI":"10.18632\/oncotarget.19888","volume":"8","author":"LA Byers","year":"2017","unstructured":"Byers LA, Horn L, Ghandi J, Kloecker G, Owonikoko T, Waqar SN, et al. A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. Oncotarget. 2017;8(46):81441\u201354.","journal-title":"Oncotarget"},{"issue":"7538","key":"1183_CR118","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MIR, et al. Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature. 2015;518(7538):258\u201362.","journal-title":"Nature"},{"issue":"1","key":"1183_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/ijc.11666","volume":"109","author":"K Kawamura","year":"2004","unstructured":"Kawamura K, Bahar R, Seimiya M, Chiyo M, Wada A, Okada S, et al. DNA polymerase theta is preferentially expressed in lymphoid tissues and upregulated in human cancers. Int J Cancer. 2004;109(1):9\u201316.","journal-title":"Int J Cancer"},{"issue":"1","key":"1183_CR120","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1038\/s41467-019-12234-1","volume":"10","author":"W Feng","year":"2019","unstructured":"Feng W, Simpson DA, Carvajal-Garcia J, Price BA, Kumar RJ, Mose LE, et al. Genetic determinants of cellular addiction to DNA polymerase theta. Nat Commun. 2019;10(1):4286.","journal-title":"Nat Commun"},{"issue":"6","key":"1183_CR121","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","volume":"2","author":"J Zhou","year":"2021","unstructured":"Zhou J, Gelot C, Pantelidou C, Li A, Y\u00fccel H, Davis RE, et al. A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nat Cancer. 2021;2(6):598\u2013610.","journal-title":"Nat Cancer"},{"issue":"1","key":"1183_CR122","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","volume":"12","author":"D Zatreanu","year":"2021","unstructured":"Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, et al. Pol\u03b8 inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021;12(1):3636.","journal-title":"Nat Commun"},{"issue":"8","key":"1183_CR123","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/1078-0432.CCR-22-2977","volume":"29","author":"G Rodriguez-Berriguete","year":"2023","unstructured":"Rodriguez-Berriguete G, Ranzani M, Prevo R, Puliyadi R, Machado N, Bolland HR, et al. Small-molecule Pol\u03b8 inhibitors provide safe and effective tumor radiosensitization in preclinical models. Clin Cancer Res. 2023;29(8):1631\u201342.","journal-title":"Clin Cancer Res"},{"issue":"7753","key":"1183_CR124","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568(7753):511\u20136.","journal-title":"Nature"},{"key":"1183_CR125","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.isci.2019.02.006","volume":"13","author":"L Kategaya","year":"2019","unstructured":"Kategaya L, Perumal SK, Hager JH, Belmont LD. Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability. iScience. 2019;13:488\u201397.","journal-title":"iScience"},{"key":"1183_CR126","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43333","volume":"8","author":"S Lieb","year":"2019","unstructured":"Lieb S, Blaha-Ostermann S, Kamper E, Rippka J, Schwarz C, Ehrenh\u00f6fer-W\u00f6lfer K, et al. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife. 2019;8:e43333.","journal-title":"Elife"},{"issue":"7753","key":"1183_CR127","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41586-019-1102-x","volume":"568","author":"EM Chan","year":"2019","unstructured":"Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551\u20136.","journal-title":"Nature"},{"issue":"7828","key":"1183_CR128","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41586-020-2769-8","volume":"586","author":"N van Wietmarschen","year":"2020","unstructured":"van Wietmarschen N, Sridharan S, Nathan WJ, Tubbs A, Chan EM, Callen E, et al. Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature. 2020;586(7828):292\u20138.","journal-title":"Nature"},{"issue":"23","key":"1183_CR129","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"key":"1183_CR130","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2025.02.021","volume":"195","author":"G Fuc\u00e0","year":"2025","unstructured":"Fuc\u00e0 G, Dell\u2019Acqua C, Peruffo B, Lalli G, Sabatucci I, Paderno M, et al. WRN dependency in dMMR\/MSI-H endometrial cancer: clinical perspectives of a novel synthetic lethality strategy. Gynecol Oncol. 2025;195:12\u20135.","journal-title":"Gynecol Oncol"},{"issue":"8_Suppl._2","key":"1183_CR131","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT016","volume":"85","author":"TA Yap","year":"2025","unstructured":"Yap TA, Cook N, Fontana E, Tsang ES, Bechter O, Fakih M, et al. Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and\/or mismatch repair deficient (dMMR) advanced solid tumors. Cancer Res. 2025;85(8_Suppl._2):CT016.","journal-title":"Cancer Res"},{"issue":"8011","key":"1183_CR132","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","volume":"629","author":"S Ferretti","year":"2024","unstructured":"Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature. 2024;629(8011):443\u20139.","journal-title":"Nature"},{"issue":"8011","key":"1183_CR133","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","volume":"629","author":"KA Baltgalvis","year":"2024","unstructured":"Baltgalvis KA, Lamb KN, Symons KT, Wu CC, Hoffman MA, Snead AN, et al. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature. 2024;629(8011):435\u201342.","journal-title":"Nature"},{"issue":"11","key":"1183_CR134","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.chembiol.2011.08.014","volume":"18","author":"J Chen","year":"2011","unstructured":"Chen J, Dexheimer TS, Ai Y, Liang Q, Villamil MA, Inglese J, et al. Selective and cell-active inhibitors of the USP1\/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18(11):1390\u2013400.","journal-title":"Chem Biol"},{"issue":"13_Suppl","key":"1183_CR135","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1337","volume":"81","author":"S Shenker","year":"2021","unstructured":"Shenker S, Gannon H, Carlson A, Grasberger P, Sullivan P, Middleton C, et al. Abstract 1337: functional genomic characterization of the USP1 inhibitor KSQ-4279 reveals a distinct mechanism of action and resistance profile relative to other DDR targeting drugs. Cancer Res. 2021;81(13_Suppl):1337.","journal-title":"Cancer Res"},{"issue":"5","key":"1183_CR136","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/1535-7163.MCT-24-0515","volume":"24","author":"A Simoneau","year":"2025","unstructured":"Simoneau A, Pratt CB, Wu HJ, Rajeswaran SS, Comer CG, Sudsakorn S, et al. Characterization of TNG348: a selective, allosteric USP1 inhibitor that synergizes with PARP inhibitors in tumors with homologous recombination deficiency. Mol Cancer Ther. 2025;24(5):678\u201391.","journal-title":"Mol Cancer Ther"},{"issue":"7_Suppl","key":"1183_CR137","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB271","volume":"84","author":"S Yang","year":"2024","unstructured":"Yang S, Li Z, Zhou L, Zhou F, Qin X, Xue L, et al. Abstract LB271: synergistic anti-tumor efficacy in olaparib-sensitive and -resistant models via simultaneously inhibition of USP1 and PARP. Cancer Res. 2024;84(7_Suppl):LB271.","journal-title":"Cancer Res"},{"issue":"8_Suppl._1","key":"1183_CR138","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-5723","volume":"85","author":"A Charruyer-Reinwald","year":"2025","unstructured":"Charruyer-Reinwald A, Kumar A, Lai J, Simonovich S, Kochansky C, DeMicco A, et al. Abstract 5723: XL309 is a potent, selective, and orally bioavailable USP1 inhibitor active as monotherapy and in combination with PARP inhibitors or irinotecan. Cancer Res. 2025;85(8_Suppl._1):5723.","journal-title":"Cancer Res"},{"issue":"16_Suppl.","key":"1183_CR139","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3005","volume":"42","author":"TA Yap","year":"2024","unstructured":"Yap TA, Lakhani NJ, Patnaik A, Lee EK, Gutierrez M, Moore KN, et al. First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. J Clin Oncol. 2024;42(16_Suppl.):3005.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1183_CR140","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2019.02.004","volume":"35","author":"N Pillay","year":"2019","unstructured":"Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, et al. DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-ribose) glycohydrolase inhibitors. Cancer Cell. 2019;35(3):519-33.e8.","journal-title":"Cancer Cell"},{"issue":"15","key":"1183_CR141","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1158\/0008-5472.CAN-18-1037","volume":"79","author":"Y Sasaki","year":"2019","unstructured":"Sasaki Y, Fujimori H, Hozumi M, Onodera T, Nozaki T, Murakami Y, et al. Dysfunction of poly (ADP-ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells. Cancer Res. 2019;79(15):3851\u201361.","journal-title":"Cancer Res"},{"issue":"6","key":"1183_CR142","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s44318-024-00043-2","volume":"43","author":"C Andronikou","year":"2024","unstructured":"Andronikou C, Burdova K, Dibitetto D, Lieftink C, Malzer E, Kuiken HJ, et al. PARG-deficient tumor cells have an increased dependence on EXO1\/FEN1-mediated DNA repair. EMBO J. 2024;43(6):1015\u201342.","journal-title":"EMBO J"},{"issue":"7_Suppl.","key":"1183_CR143","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6093","volume":"83","author":"M Abed","year":"2023","unstructured":"Abed M, Mu\u00f1oz D, Seshadri V, Federowicz S, Rao AA, Bhupathi D, et al. Abstract 6093: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors. Cancer Res. 2023;83(7_Suppl.):6093.","journal-title":"Cancer Res"},{"issue":"8_Suppl._1","key":"1183_CR144","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2899","volume":"85","author":"R Maskey","year":"2025","unstructured":"Maskey R, Conway M, Lim PX, Donahue AC, Fitz E, Nagarajan V, et al. Abstract 2899: PARG inhibition provokes a DNA damage-dependent innate immune reaction that enhances ICI-driven anti-tumor immunity. Cancer Res. 2025;85(8_Suppl._1):2899.","journal-title":"Cancer Res"},{"issue":"6_Suppl","key":"1183_CR145","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-2083","volume":"84","author":"JP Holleran","year":"2024","unstructured":"Holleran JP, Rodems TS, Sharma S, Santini AM, Wuerz C, Liu J, et al. Abstract 2083: discovery of ETX-19477, a novel and selective PARG inhibitor with high potency against tumors with underlying replication stress. Cancer Res. 2024;84(6_Suppl):2083.","journal-title":"Cancer Res"},{"issue":"6_Suppl","key":"1183_CR146","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-6011","volume":"84","author":"E Piumatti","year":"2024","unstructured":"Piumatti E, Hervieu A, Riou P, Blagg J, Peall A, Weeks S, et al. Abstract 6011: pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo. Cancer Res. 2024;84(6_Suppl):6011.","journal-title":"Cancer Res"},{"key":"1183_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.156075","volume":"272","author":"M Rejili","year":"2025","unstructured":"Rejili M. Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy. Pathol Res Pract. 2025;272:156075.","journal-title":"Pathol Res Pract"},{"key":"1183_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115522","volume":"224","author":"JM Porter","year":"2025","unstructured":"Porter JM, Jin C, Churchman M, Croy I, Gourley CM, Glyn-Wright O, et al. Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer. Eur J Cancer. 2025;224:115522.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1183_CR149","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","volume":"34","author":"L Xing","year":"2020","unstructured":"Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, et al. A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020;34(8):2150\u201362.","journal-title":"Leukemia"},{"issue":"3","key":"1183_CR150","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1535-7163.MCT-20-0351","volume":"20","author":"S Mao","year":"2021","unstructured":"Mao S, Chaerkady R, Yu W, D\u2019Angelo G, Garcia A, Chen H, et al. Resistance to pyrrolobenzodiazepine dimers is associated with SLFN11 downregulation and can be reversed through inhibition of ATR. Mol Cancer Ther. 2021;20(3):541\u201352.","journal-title":"Mol Cancer Ther"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01183-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01183-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01183-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T17:09:58Z","timestamp":1764608998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01183-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":150,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01183-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eve Merry has no conflicts of interest that are directly relevant to the content of this article. Charlie Gourley has received research grants from AstraZeneca, GSK, MSD, BergenBio, Novartis, Aprea, Nucana, Versatem, Roche, Medannexin, Artios and AbbVie; consulting fees from AstraZeneca, MSD, GSK, Verastem, AbbVie, Immunogen and Pharma&; speaker fees from AstraZeneca, MSD, GSK, Cor2Ed, Verastem, AbbVie, Immunogen and Pharma&; fees for participation on a data safety monitoring board\/advisory board from AstraZeneca and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"EM and CG contributed to the preparation and research for the manuscript and EM wrote the manuscript. EM and CG edited and reviewed the manuscript prior to submission.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}